The Substance Abuse and Mental Health Services Administration yesterday extended certain methadone take-home flexibilities for opioid treatment programs until one year after the end of the COVID-19 public health emergency, and said it is considering ways to make the flexibilities permanent. 

SAMHSA in 2020 allowed states to request a blanket exception to allow stable patients in an opioid treatment program to receive 28 days of take-home doses of their OUD medication, and other eligible patients to receive up to 14 days of take-home medication, which the agency said has enhanced and encouraged use of treatment services.
 

Related News Articles

Headline
In this podcast, Rebecca Chickey, AHA’s senior director of field engagement and behavioral health services, speaks with leaders from Allina Health in…
Headline
Primary and behavioral health organizations, state and local governments and others can apply through Feb. 7 for a portion of $30 million from the American…
Headline
The Department of Health and Human Services today released an overdose prevention strategy focused on prevention, harm reduction, evidence-based treatment…
Headline
Nearly three-fourths of the 2.4 million U.S. adults who reported using buprenorphine in 2019 did not misuse the medication in the past 12 months, according to…
Headline
U.S. overdose deaths involving psychostimulants other than cocaine, largely methamphetamine, increased 180% among adults under age 65 between 2015 and 2019, to…
Headline
The Brigham Comprehensive Opioid Response and Education program and McLean Hospital of Belmont, Mass., on Sept. 21 at 12 p.m. ET will host a town hall virtual…